Legend Biotech Corp (NASDAQ:LEGN) makes the list of the 13 Best Revenue Growth Stocks to Buy Right Now. The company recently saw a board shakeup, with Robin Meng appointed as a new director. Li Zhu and Yau Wai Man Philip resigned, with no disputes reported.

H. C. Wainwright lowered LEGN’s price target to $50, while TD Cowen downgraded the stock to Hold with a $21 price target. Legend Biotech reported $555 million in net trade sales for its CARVYKTI therapy. The company focuses on developing novel therapies for oncology and other indications, attracting investor interest.

Read more at Yahoo Finance: Legend Biotech (LEGN) Shakes Up Board